Home LiteratureArticle Details
PMID: 20029421 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Integrins in cancer: biological implications and therapeutic opportunities.

Nature reviews. Cancer ·Vol. 10 ·No. 1 ·2010-01-00 ·Pages 9-22

Desgrosellier JS, Cheresh DA

Abstract

The integrin family of cell adhesion receptors regulates a diverse array of cellular functions crucial to the initiation, progression and metastasis of solid tumours. The importance of integrins in several cell types that affect tumour progression has made them an appealing target for cancer therapy. Integrin antagonists, including the alphavbeta3 and alphavbeta5 inhibitor cilengitide, have shown encouraging activity in Phase II clinical trials and cilengitide is currently being tested in a Phase III trial in patients with glioblastoma. These exciting clinical developments emphasize the need to identify how integrin antagonists influence the tumour and its microenvironment.

MeSH Terms
Animals Apoptosis Clinical Trials as Topic Humans Integrins/antagonists & inhibitors,metabolism,therapeutic use Neoplasms/drug therapy,metabolism,pathology,physiopathology Signal Transduction
Chemicals
Integrins
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Desgrosellier Jay S
Department of Pathology, Moores University of California at San Diego Cancer Center, La Jolla, 92093-0803, United States.
Cheresh David A
References (195)
195 references, click to expand
  1. Unoccupied alpha(v)beta3 integrin regulates osteoclast apoptosis by transmitting a positive death signal.
    Mol Endocrinol. 2005 Mar;19(3):771-80 PMID: 15591537
  2. Beta3 integrin and Src facilitate transforming growth factor-beta mediated induction of epithelial-mesenchymal transition in mammary epithelial cells.
    Breast Cancer Res. 2006;8(4):R42 PMID: 16859511
  3. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction.
    Cancer Cell. 2004 Aug;6(2):159-70 PMID: 15324699
  4. Increased primary tumor growth in mice null for beta3- or beta3/beta5-integrins or selectins.
    Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):763-8 PMID: 14718670
  5. Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.
    Int J Cancer. 2007 Feb 1;120(3):605-10 PMID: 17096340
  6. Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells.
    Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7411-5 PMID: 7638207
  7. Osteoblasts-derived TGF-beta1 enhance motility and integrin upregulation through Akt, ERK, and NF-kappaB-dependent pathway in human breast cancer cells.
    Mol Carcinog. 2008 Jul;47(7):526-37 PMID: 18161870
  8. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins.
    J Cell Biol. 2001 Oct 29;155(3):459-70 PMID: 11684710
  9. Integrin alphav-mediated inactivation of p53 controls a MEK1-dependent melanoma cell survival pathway in three-dimensional collagen.
    J Cell Biol. 2004 Nov 22;167(4):745-56 PMID: 15557124
  10. Integrin alpha4beta1 promotes monocyte trafficking and angiogenesis in tumors.
    Cancer Res. 2006 Feb 15;66(4):2146-52 PMID: 16489015
  11. Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion.
    Cancer Res. 2007 Apr 15;67(8):3752-8 PMID: 17440088
  12. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins.
    J Biol Chem. 1994 Aug 12;269(32):20233-8 PMID: 8051114
  13. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
    Cancer Cell. 2009 Mar 3;15(3):232-9 PMID: 19249681
  14. Prostate cancer specific integrin alphavbeta3 modulates bone metastatic growth and tissue remodeling.
    Oncogene. 2007 Sep 13;26(42):6238-43 PMID: 17369840
  15. Human melanoma cells derived from lymphatic metastases use integrin alpha v beta 3 to adhere to lymph node vitronectin.
    J Clin Invest. 1992 Oct;90(4):1406-13 PMID: 1383272
  16. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
    J Clin Oncol. 2010 Jun 1;28(16):2712-8 PMID: 20439646
  17. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
    J Clin Oncol. 2008 Dec 1;26(34):5610-7 PMID: 18981465
  18. High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival.
    Cancer Res. 1995 Feb 15;55(4):901-6 PMID: 7850807
  19. Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells.
    J Cell Biol. 1990 Apr;110(4):1427-38 PMID: 2324200
  20. Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins.
    Circulation. 2003 Jan 28;107(3):455-60 PMID: 12551871
  21. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels.
    Cell. 1994 Dec 30;79(7):1157-64 PMID: 7528107
  22. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.
    Cancer Res. 2006 Oct 1;66(19):9673-81 PMID: 17018625
  23. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design.
    Clin Genitourin Cancer. 2006 Mar;4(4):299-302 PMID: 16729916
  24. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2.
    EMBO J. 1999 Feb 15;18(4):882-92 PMID: 10022831
  25. Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis.
    Cancer Res. 2009 Feb 15;69(4):1383-91 PMID: 19208836
  26. Expression of integrin alphaVbeta3 in pancreatic carcinoma: relation to MMP-2 activation and lymph node metastasis.
    Pancreas. 2002 Aug;25(2):e30-5 PMID: 12142752
  27. Platelet and osteoclast beta3 integrins are critical for bone metastasis.
    Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14205-10 PMID: 14612570
  28. Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice.
    Neurosurgery. 2006 Dec;59(6):1304-12; discussion 1312 PMID: 17277694
  29. A signaling pathway from the alpha5beta1 and alpha(v)beta3 integrins that elevates bcl-2 transcription.
    J Biol Chem. 2001 Jul 27;276(30):27757-63 PMID: 11333270
  30. The Met receptor and alpha 6 beta 4 integrin can function independently to promote carcinoma invasion.
    J Biol Chem. 2004 Jul 30;279(31):32287-93 PMID: 15161909
  31. Integrin activation controls metastasis in human breast cancer.
    Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1853-8 PMID: 11172040
  32. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells.
    Cancer Res. 2009 Jan 15;69(2):466-74 PMID: 19147559
  33. Phase I trial of a monoclonal antibody specific for alphavbeta3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion.
    Clin Cancer Res. 2005 Nov 1;11(21):7851-60 PMID: 16278408
  34. Integrin alpha 5 beta 1 expression negatively regulates cell growth: reversal by attachment to fibronectin.
    Mol Biol Cell. 1995 Jun;6(6):725-40 PMID: 7579691
  35. Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides.
    Eur J Biochem. 1992 Dec 15;210(3):911-21 PMID: 1483474
  36. Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis.
    Cancer Res. 2005 Dec 1;65(23):10674-9 PMID: 16322210
  37. The angiogenic response is dictated by beta3 integrin on bone marrow-derived cells.
    J Cell Biol. 2008 Dec 15;183(6):1145-57 PMID: 19075116
  38. ILK, PINCH and parvin: the tIPP of integrin signalling.
    Nat Rev Mol Cell Biol. 2006 Jan;7(1):20-31 PMID: 16493410
  39. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins.
    Nat Med. 2002 Jan;8(1):27-34 PMID: 11786903
  40. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor.
    Proc Natl Acad Sci U S A. 1987 Sep;84(18):6471-5 PMID: 2442758
  41. The desmoplastic reaction surrounding hepatic colorectal adenocarcinoma metastases aids tumor growth and survival via alphav integrin ligation.
    Clin Cancer Res. 2008 Oct 15;14(20):6405-13 PMID: 18927279
  42. Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface.
    J Cell Biol. 1991 May;113(4):919-29 PMID: 1709170
  43. Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.
    Clin Cancer Res. 2007 Apr 1;13(7):2128-35 PMID: 17404096
  44. Loss of integrin alpha1beta1 ameliorates Kras-induced lung cancer.
    Cancer Res. 2008 Aug 1;68(15):6127-35 PMID: 18676835
  45. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging.
    Cancer Res. 2003 Sep 15;63(18):5838-43 PMID: 14522907
  46. Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo.
    J Clin Invest. 1997 Mar 15;99(6):1390-8 PMID: 9077549
  47. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells.
    J Clin Invest. 1991 Dec;88(6):1924-32 PMID: 1721625
  48. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice.
    Int J Cancer. 2003 Apr 20;104(4):496-503 PMID: 12584749
  49. A mechanism for modulation of cellular responses to VEGF: activation of the integrins.
    Mol Cell. 2000 Oct;6(4):851-60 PMID: 11090623
  50. Tetraspanins: push and pull in suppressing and promoting metastasis.
    Nat Rev Cancer. 2009 Jan;9(1):40-55 PMID: 19078974
  51. AlphaVbeta3 integrin regulates heregulin (HRG)-induced cell proliferation and survival in breast cancer.
    Oncogene. 2005 May 26;24(23):3759-73 PMID: 15782133
  52. MicroPET imaging of brain tumor angiogenesis with 18F-labeled PEGylated RGD peptide.
    Eur J Nucl Med Mol Imaging. 2004 Aug;31(8):1081-9 PMID: 15118844
  53. Fibronectin fragments released from phorbol ester-stimulated pulmonary artery endothelial cell monolayers promote neutrophil chemotaxis.
    Immunology. 1991 Sep;74(1):114-20 PMID: 1937565
  54. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging.
    Nat Med. 1998 May;4(5):623-6 PMID: 9585240
  55. Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression.
    Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20302-7 PMID: 18056629
  56. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.
    Invest New Drugs. 2008 Feb;26(1):35-43 PMID: 17876527
  57. Integrins uncouple Src-induced morphological and oncogenic transformation.
    J Biol Chem. 2008 May 9;283(19):13243-51 PMID: 18326486
  58. Growth control by intracellular tension and extracellular stiffness.
    Trends Cell Biol. 2008 Jul;18(7):347-52 PMID: 18514521
  59. Effects of Vitaxin, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro.
    J Cell Biochem. 2007 Oct 1;102(2):341-52 PMID: 17390341
  60. Src kinase activity is required for integrin alphaVbeta3-mediated activation of nuclear factor-kappaB.
    J Biol Chem. 2005 Apr 1;280(13):12145-51 PMID: 15695822
  61. Alpha-V-dependent outside-in signaling is required for the regulation of CD44 surface expression, MMP-2 secretion, and cell migration by osteopontin in human melanoma cells.
    Exp Cell Res. 2006 Jul 15;312(12):2214-30 PMID: 16631740
  62. Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012.
    J Clin Oncol. 2008 Feb 20;26(6):919-24 PMID: 18281665
  63. Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival.
    J Pathol. 2007 Jul;212(3):316-24 PMID: 17503414
  64. ERBB2-mediated transcriptional up-regulation of the alpha5beta1 integrin fibronectin receptor promotes tumor cell survival under adverse conditions.
    Cancer Res. 2006 Apr 1;66(7):3715-25 PMID: 16585198
  65. A role for VEGF as a negative regulator of pericyte function and vessel maturation.
    Nature. 2008 Dec 11;456(7223):809-13 PMID: 18997771
  66. The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression.
    Anticancer Res. 2005 Jan-Feb;25(1A):79-83 PMID: 15816522
  67. Affinity of integrins for damaged extracellular matrix: alpha v beta 3 binds to denatured collagen type I through RGD sites.
    Biochem Biophys Res Commun. 1992 Feb 14;182(3):1025-31 PMID: 1540151
  68. Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow.
    J Biol Chem. 1996 Mar 8;271(10):5892-900 PMID: 8621462
  69. Drug evaluation: Volociximab, an angiogenesis-inhibiting chimeric monoclonal antibody.
    Curr Opin Mol Ther. 2007 Feb;9(1):92-8 PMID: 17330407
  70. Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.
    J Clin Invest. 2009 Feb;119(2):252-66 PMID: 19147981
  71. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis.
    Clin Exp Metastasis. 2004;21(2):119-28 PMID: 15168729
  72. Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton.
    Cancer Res. 2009 Jan 15;69(2):475-82 PMID: 19147560
  73. Emergence of alpha 5 beta 1 fibronectin- and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression.
    Histopathology. 1994 Mar;24(3):249-56 PMID: 7515372
  74. Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model.
    Cancer Res. 2002 Nov 1;62(21):6146-51 PMID: 12414640
  75. Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis.
    Cancer Res. 2009 Feb 15;69(4):1469-76 PMID: 19208843
  76. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours.
    Br J Cancer. 2006 Jun 5;94(11):1621-6 PMID: 16705310
  77. Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas.
    Dig Liver Dis. 2007 Jun;39(6):557-65 PMID: 17374519
  78. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases.
    Diagn Mol Pathol. 1996 Jun;5(2):127-35 PMID: 8727100
  79. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases.
    Cancer Res. 2007 Jun 15;67(12):5821-30 PMID: 17575150
  80. Integrin alpha(v)beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival.
    Cancer Res. 1999 Jun 1;59(11):2724-30 PMID: 10363998
  81. Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone.
    Breast Cancer Res. 2006;8(2):R20 PMID: 16608535
  82. Increased tumor cell dissemination and cellular senescence in the absence of beta1-integrin function.
    EMBO J. 2007 Jun 20;26(12):2832-42 PMID: 17541405
  83. Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain.
    J Biol Chem. 2000 Dec 22;275(51):39867-73 PMID: 10964931
  84. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.
    Cancer Cell. 2009 Mar 3;15(3):220-31 PMID: 19249680
  85. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner.
    Cancer Res. 2007 Feb 15;67(4):1555-62 PMID: 17308094
  86. Integrin-induced epidermal growth factor (EGF) receptor activation requires c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines.
    J Biol Chem. 2002 Mar 15;277(11):9405-14 PMID: 11756413
  87. MicroPET imaging of breast cancer alphav-integrin expression with 64Cu-labeled dimeric RGD peptides.
    Mol Imaging Biol. 2004 Sep-Oct;6(5):350-9 PMID: 15380745
  88. alpha v beta3 and alpha5beta1 integrin recycling pathways dictate downstream Rho kinase signaling to regulate persistent cell migration.
    J Cell Biol. 2007 May 7;177(3):515-25 PMID: 17485491
  89. Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells.
    Prostate. 2007 Jan 1;67(1):61-73 PMID: 17034033
  90. Elevated levels of the alpha 5 beta 1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells.
    Cell. 1990 Mar 9;60(5):849-59 PMID: 2155708
  91. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits.
    Invest New Drugs. 2008 Feb;26(1):7-12 PMID: 17786386
  92. Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits.
    FASEB J. 2008 Aug;22(8):2758-67 PMID: 18362202
  93. Integrins in angiogenesis and lymphangiogenesis.
    Nat Rev Cancer. 2008 Aug;8(8):604-17 PMID: 18497750
  94. Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells.
    Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11754-9 PMID: 17600088
  95. Rac-dependent cyclin D1 gene expression regulated by cadherin- and integrin-mediated adhesion.
    J Cell Sci. 2008 Jan 15;121(Pt 2):226-33 PMID: 18187454
  96. Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding.
    Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6959-65 PMID: 16203788
  97. An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression.
    Nat Med. 2009 Oct;15(10):1163-9 PMID: 19734908
  98. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis.
    Cell. 2006 Aug 11;126(3):489-502 PMID: 16901783
  99. Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo.
    Mol Ther. 2009 Jun;17(6):1012-21 PMID: 19277014
  100. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD.
    PLoS Med. 2005 Mar;2(3):e70 PMID: 15783258
  101. Rab-coupling protein coordinates recycling of alpha5beta1 integrin and EGFR1 to promote cell migration in 3D microenvironments.
    J Cell Biol. 2008 Oct 6;183(1):143-55 PMID: 18838556
  102. A direct test of potential roles for beta3 and beta5 integrins in growth and metastasis of murine mammary carcinomas.
    Cancer Res. 2005 Nov 15;65(22):10324-9 PMID: 16288021
  103. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells.
    Oncogene. 2001 Aug 16;20(36):4995-5004 PMID: 11526484
  104. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.
    Neoplasia. 2008 Nov;10(11):1259-67 PMID: 18953435
  105. Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth.
    J Cell Biol. 2006 Dec 18;175(6):993-1003 PMID: 17158954
  106. Receptor tyrosine kinase signaling required for integrin alpha v beta 5-directed cell motility but not adhesion on vitronectin.
    J Cell Biol. 1994 Nov;127(3):859-66 PMID: 7525598
  107. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases.
    Oncogene. 2006 Apr 13;25(16):2367-78 PMID: 16331263
  108. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery.
    Neurosurgery. 2001 Aug;49(2):380-9; discussion 390 PMID: 11504114
  109. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist.
    Neurosurgery. 2001 Jan;48(1):151-7 PMID: 11152340
  110. The mammary progenitor marker CD61/beta3 integrin identifies cancer stem cells in mouse models of mammary tumorigenesis.
    Cancer Res. 2008 Oct 1;68(19):7711-7 PMID: 18829523
  111. Differential alphav integrin-mediated Ras-ERK signaling during two pathways of angiogenesis.
    J Cell Biol. 2003 Sep 1;162(5):933-43 PMID: 12952943
  112. Significance of integrin alpha5 gene expression as a prognostic factor in node-negative non-small cell lung cancer.
    Clin Cancer Res. 2000 Jan;6(1):96-101 PMID: 10656437
  113. Laminin-10 mediates basal and EGF-stimulated motility of human colon carcinoma cells via alpha(3)beta(1) and alpha(6)beta(4) integrins.
    Exp Cell Res. 2001 May 15;266(1):1-10 PMID: 11339819
  114. CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells.
    Clin Exp Metastasis. 2008;25(2):139-48 PMID: 18064530
  115. Reconstructing and deconstructing agonist-induced activation of integrin alphaIIbbeta3.
    Curr Biol. 2006 Sep 19;16(18):1796-806 PMID: 16979556
  116. Distinct FAK-Src activation events promote alpha5beta1 and alpha4beta1 integrin-stimulated neuroblastoma cell motility.
    Oncogene. 2008 Feb 28;27(10):1439-48 PMID: 17828307
  117. The contribution of Harold F. Dvorak to the study of tumor angiogenesis and stroma generation mechanisms.
    Endothelium. 2007 May-Jun;14(3):131-5 PMID: 17578706
  118. Role of Raf in vascular protection from distinct apoptotic stimuli.
    Science. 2003 Jul 4;301(5629):94-6 PMID: 12843393
  119. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma.
    Hepatology. 2009 Mar;49(3):839-50 PMID: 19115199
  120. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins.
    Neoplasia. 2006 Apr;8(4):290-301 PMID: 16756721
  121. Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis.
    J Cell Biol. 2001 Feb 5;152(3):633-43 PMID: 11157988
  122. Potentiation of neuroblastoma metastasis by loss of caspase-8.
    Nature. 2006 Jan 5;439(7072):95-9 PMID: 16397500
  123. Role of the F-box protein Skp2 in adhesion-dependent cell cycle progression.
    J Cell Biol. 2001 Jun 25;153(7):1381-90 PMID: 11425869
  124. Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors.
    J Cell Biol. 1996 Dec;135(6 Pt 1):1633-42 PMID: 8978828
  125. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.
    Cancer Res. 2008 Jan 15;68(2):561-70 PMID: 18199553
  126. Integrin signalling during tumour progression.
    Nat Rev Mol Cell Biol. 2004 Oct;5(10):816-26 PMID: 15459662
  127. Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization.
    Microvasc Res. 2007 Sep-Nov;74(2-3):72-84 PMID: 17560615
  128. Correlation between the tumoral expression of beta3-integrin and outcome in cervical cancer patients who had undergone radiotherapy.
    Br J Cancer. 2005 Jan 17;92(1):41-6 PMID: 15597101
  129. Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma.
    J Clin Invest. 2005 Feb;115(2):339-47 PMID: 15668738
  130. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis.
    Cell. 1999 Feb 5;96(3):319-28 PMID: 10025398
  131. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.
    Clin Cancer Res. 2000 Aug;6(8):3056-61 PMID: 10955784
  132. CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin.
    Cancer Res. 2003 Oct 15;63(20):6751-7 PMID: 14583470
  133. Requirement of vascular integrin alpha v beta 3 for angiogenesis.
    Science. 1994 Apr 22;264(5158):569-71 PMID: 7512751
  134. Lipopeptide with a RGDK tetrapeptide sequence can selectively target genes to proangiogenic alpha5beta1 integrin receptor and mouse tumor vasculature.
    J Med Chem. 2008 Nov 27;51(22):7298-302 PMID: 18956861
  135. Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice.
    Cancer Res. 2004 Dec 1;64(23):8643-50 PMID: 15574772
  136. Cellular abnormalities of blood vessels as targets in cancer.
    Curr Opin Genet Dev. 2005 Feb;15(1):102-11 PMID: 15661540
  137. Vitronectin, a glioma-derived extracellular matrix protein, protects tumor cells from apoptotic death.
    Clin Cancer Res. 1999 Jun;5(6):1587-94 PMID: 10389948
  138. Mechanisms of integrin-vascular endothelial growth factor receptor cross-activation in angiogenesis.
    Circ Res. 2007 Sep 14;101(6):570-80 PMID: 17641225
  139. Integrin scintimammography using a dedicated breast imaging, solid-state gamma-camera and (99m)Tc-labelled NC100692.
    Clin Physiol Funct Imaging. 2008 Jul;28(4):235-9 PMID: 18384623
  140. Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1.
    FEBS Lett. 1991 Oct 7;291(1):50-4 PMID: 1718779
  141. Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study.
    Clin Cancer Res. 2008 Dec 1;14(23):7924-9 PMID: 19047123
  142. Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation.
    J Clin Invest. 2005 Jun;115(6):1542-51 PMID: 15902308
  143. A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.
    J Transl Med. 2007 Nov 27;5:61 PMID: 18042290
  144. Integrin-mediated laminin-1 adhesion upregulates CXCR4 and IL-8 expression in pancreatic cancer cells.
    Surgery. 2007 Jun;141(6):804-14 PMID: 17560257
  145. Integrins induce activation of EGF receptor: role in MAP kinase induction and adhesion-dependent cell survival.
    EMBO J. 1998 Nov 16;17(22):6622-32 PMID: 9822606
  146. Interaction of integrins alpha v beta 3 and glycoprotein IIb-IIIa with fibrinogen. Differential peptide recognition accounts for distinct binding sites.
    J Biol Chem. 1990 Jul 25;265(21):12267-71 PMID: 2373693
  147. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.
    Cancer Res. 2006 Mar 1;66(5):2732-9 PMID: 16510594
  148. HGF and ligation of alphavbeta5 integrin induce a novel, cancer cell-specific gene expression required for cell scattering.
    Exp Cell Res. 2004 Jan 15;292(2):274-87 PMID: 14697335
  149. Cooperation between VEGF and beta3 integrin during cardiac vascular development.
    Blood. 2007 Mar 1;109(5):1962-70 PMID: 17062734
  150. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells.
    Oncogene. 2005 Jun 23;24(27):4462-71 PMID: 15806155
  151. Integrin beta4 signaling promotes tumor angiogenesis.
    Cancer Cell. 2004 Nov;6(5):471-83 PMID: 15542431
  152. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival.
    J Cell Biol. 1998 May 18;141(4):1083-93 PMID: 9585425
  153. Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692.
    J Nucl Med. 2006 Sep;47(9):1434-9 PMID: 16954550
  154. Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma.
    Am J Pathol. 1998 Nov;153(5):1435-42 PMID: 9811334
  155. Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation.
    Cancer Res. 2005 Oct 15;65(20):9280-6 PMID: 16230389
  156. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo.
    Mol Cancer Ther. 2006 Sep;5(9):2271-80 PMID: 16985061
  157. Superactivation of integrin alphavbeta3 by low antagonist concentrations.
    J Cell Sci. 2001 Apr;114(Pt 8):1545-53 PMID: 11282030
  158. Alpha6beta1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells.
    Oncogene. 2003 Feb 13;22(6):831-9 PMID: 12584562
  159. Cell-matrix adhesion.
    J Cell Physiol. 2007 Dec;213(3):565-73 PMID: 17680633
  160. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression.
    Cancer Res. 1990 Oct 15;50(20):6757-64 PMID: 2208139
  161. Identification and isolation of a 140 kd cell surface glycoprotein with properties expected of a fibronectin receptor.
    Cell. 1985 Jan;40(1):191-8 PMID: 3155652
  162. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth.
    Cell. 2001 Nov 30;107(5):643-54 PMID: 11733063
  163. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.
    J Clin Invest. 1995 Oct;96(4):1815-22 PMID: 7560073
  164. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.
    J Clin Oncol. 2007 May 1;25(13):1651-7 PMID: 17470857
  165. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature.
    Mol Cancer Ther. 2008 Apr;7(4):851-61 PMID: 18413798
  166. Beta4 integrin subunit gene expression correlates with tumor size and nuclear grade in early breast cancer.
    Mod Pathol. 2005 Sep;18(9):1165-75 PMID: 15920552
  167. Activated epidermal growth factor receptor induces integrin alpha2 internalization via caveolae/raft-dependent endocytic pathway.
    J Biol Chem. 2007 Mar 2;282(9):6380-7 PMID: 17179151
  168. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature.
    J Clin Invest. 2006 Mar;116(3):652-62 PMID: 16498499
  169. Cell adhesion protein receptors as targets for transforming growth factor-beta action.
    Cell. 1987 Oct 23;51(2):189-97 PMID: 3499229
  170. Tumor regression by targeted gene delivery to the neovasculature.
    Science. 2002 Jun 28;296(5577):2404-7 PMID: 12089446
  171. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis.
    Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9343-8 PMID: 18607000
  172. Integrin alpha v beta 3 controls activity and oncogenic potential of primed c-Src.
    Cancer Res. 2007 Mar 15;67(6):2693-700 PMID: 17363590
  173. Integrin beta 3 cDNA transfection into a highly metastatic alpha v beta 3-negative human melanoma cell line inhibits invasion and experimental metastasis.
    Biochem Biophys Res Commun. 1996 Sep 4;226(1):75-81 PMID: 8806594
  174. Anoikis mechanisms.
    Curr Opin Cell Biol. 2001 Oct;13(5):555-62 PMID: 11544023
  175. Integrin beta3 overexpression suppresses tumor growth in a human model of gliomagenesis: implications for the role of beta3 overexpression in glioblastoma multiforme.
    Cancer Res. 2004 Apr 15;64(8):2751-8 PMID: 15087390
  176. Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme.
    Clin Cancer Res. 2008 Nov 15;14(22):7330-9 PMID: 19010848
  177. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation.
    Nat Cell Biol. 2007 Feb;9(2):201-9 PMID: 17187062
  178. Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin.
    Mol Cancer Ther. 2006 Dec;5(12):3122-9 PMID: 17172415
  179. Integrin alpha1beta1 and alpha2beta1 are the key regulators of hepatocarcinoma cell invasion across the fibrotic matrix microenvironment.
    Cancer Res. 2003 Dec 1;63(23):8312-7 PMID: 14678990
  180. Control of type II transforming growth factor-beta receptor expression by integrin ligation.
    J Biol Chem. 1999 Apr 30;274(18):12840-7 PMID: 10212271
  181. Definition of two angiogenic pathways by distinct alpha v integrins.
    Science. 1995 Dec 1;270(5241):1500-2 PMID: 7491498
  182. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo.
    Int J Cancer. 2004 Jun 20;110(3):326-35 PMID: 15095296
  183. The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3.
    Biochem J. 2003 Jan 15;369(Pt 2):311-8 PMID: 12358597
  184. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo.
    Cancer Res. 2006 Feb 1;66(3):1526-35 PMID: 16452209
  185. VEGF-integrin interplay controls tumor growth and vascularization.
    Proc Natl Acad Sci U S A. 2005 May 24;102(21):7589-94 PMID: 15897451
  186. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists.
    J Med Chem. 1999 Aug 12;42(16):3033-40 PMID: 10447947
  187. Integrin-regulated FAK-Src signaling in normal and cancer cells.
    Curr Opin Cell Biol. 2006 Oct;18(5):516-23 PMID: 16919435
  188. Alphavbeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF.
    EMBO J. 1997 Sep 15;16(18):5600-7 PMID: 9312019
  189. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice.
    Cancer Res. 2003 May 1;63(9):2079-87 PMID: 12727823
  190. Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models.
    Clin Cancer Res. 2007 Jun 15;13(12):3689-95 PMID: 17575234
  191. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma.
    Cancer. 1999 Jan 15;85(2):375-82 PMID: 10023705
  192. alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation.
    Cancer Res. 2008 May 1;68(9):3295-303 PMID: 18451156
  193. Multiple roles for platelet GPIIb/IIIa and alphavbeta3 integrins in tumor growth, angiogenesis, and metastasis.
    Cancer Res. 2002 May 15;62(10):2824-33 PMID: 12019160
  194. Anti-metastatic properties of RGD-peptidomimetic agents S137 and S247.
    Clin Exp Metastasis. 2004;21(2):129-38 PMID: 15168730
  195. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Cancer Res. 2006 Jan 1;66(1):315-23 PMID: 16397245
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc2748
Published
2010-01-00
Pages
9-22
Language
English
Region
England
NLM ID
101124168
PMCID
PMC4383089
Subset
IM
Grants
NCI NIH HHS · T32 CA121938 · United States
NCI NIH HHS · R37 CA050286 · United States
NCI NIH HHS · R01 CA045726 · United States
NCI NIH HHS · CA45726 · United States
NCI NIH HHS · R01 CA050286 · United States
NCI NIH HHS · CA50286 · United States
External Links
PubMed source DOI: 10.1038/nrc2748 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2